Wedbush Securities’s Protalix BioTherapeutics PLX Stock Holding History

Wedbush Securities’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-14,500	Closed	-$30K	–	1024
2019 Q3	$30K	Buy	14,500 +6,000	+71%	+$17.9K	﹤0.01%	962
2019 Q2	$40K	Buy	+8,500	New	+$35.9K	﹤0.01%	958
2018 Q1	–	Sell	-1,500	Closed	-$10K	–	876
2017 Q4	$10K	Sell	1,500 -800	-35%	-$5.4K	﹤0.01%	850
2017 Q3	$13K	Hold	2,300	–	–	﹤0.01%	829
2017 Q2	$19K	Buy	+2,300	New	+$21.6K	﹤0.01%	826
2017 Q1	–	Sell	-1,800	Closed	-$8K	–	872
2016 Q4	$8K	Sell	1,800 -1,200	-40%	-$5.36K	﹤0.01%	812
2016 Q3	$17K	Buy	3,000 +1,200	+67%	+$7.48K	﹤0.01%	820
2016 Q2	$12K	Hold	1,800	–	–	﹤0.01%	775
2016 Q1	$15K	Hold	1,800	–	–	﹤0.01%	737
2015 Q4	$18K	Buy	+1,800	New	+$18.3K	﹤0.01%	721

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MWPCG

Measured Wealth Private Client Group Portsmouth, New Hampshire $366M AUM 21.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wedbush Securities's PLX Position: Q4 2019 in Review

Wedbush Securities sold out of Protalix BioTherapeutics (PLX) in Q4 2019, closing a stake of 14,500 shares — an estimated $30K sold.

Wedbush Securities first reported a position in PLX in Q4 2015 and held it in 10 quarters. The position peaked at $40K in Q2 2019. 15 funds tracked by Wall St. Rank hold PLX as of Q4 2019.

Wedbush Securities reported no remaining Protalix BioTherapeutics position as of Q4 2019 after selling out during the quarter.
Wedbush Securities sold 14,500 Protalix BioTherapeutics shares in Q4 2019, an estimated $30K.
Wedbush Securities first reported a position in Protalix BioTherapeutics in Q4 2015 and held it in 10 quarters.
Wedbush Securities's Protalix BioTherapeutics position peaked at $40K in Q2 2019.
15 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2019.

Based on Wedbush Securities's 13F filing for Q4 2019, filed 16 Jan 2020.